Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes
- Authors
- Kim, Jong-Dai; Park, Cheol-Young; Cha, Bong-Yun; Ahn, Kyu Jeung; Kim, In Joo; Park, Kyong Soo; Lee, Hyung Woo; Min, Kyung-Wan; Won, Jong Chul; Chung, Min Young; Kim, Jae-Taek; Kang, Jun Goo; Park, Sung-Woo
- Issue Date
- May-2018
- Publisher
- ELSEVIER
- Keywords
- fixed dose combination; MEMS; sulfonylurea; glimepiride
- Citation
- CLINICAL THERAPEUTICS, v.40, no.5, pp 752 - 761
- Pages
- 10
- Journal Title
- CLINICAL THERAPEUTICS
- Volume
- 40
- Number
- 5
- Start Page
- 752
- End Page
- 761
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/976
- DOI
- 10.1016/j.clinthera.2018.04.002
- ISSN
- 0149-2918
1879-114X
- Abstract
- Purpose: The purpose of this study was to compare the adherence of the glimepiride/metformin sustained release (GM-SR) once-daily fixed-dose combination and glimepiride/metformin immediate release (GM-IR) BID fixed-dose combination in type 2 diabetes therapies. Methods: An open-label, randomized, multicenter, parallel-group study was conducted at 11 hospitals in the Republic of Korea. A total of 168 patients with type 2 diabetes treated with > 4 mg of glimepiride and 1000 mg of metformin by using free or fixed-dose combination therapy for at least 2 weeks were enrolled. Patients were randomized to receive GM-SR 4/1000 mg once-daily or GM-IR 2/500 mg BID for 24 weeks. Adherence was compared by using the Medication Event Monitoring System (MEMS). Findings: A significant difference in adherence was observed between the 2 groups. Overall adherence, defined by the number of container openings divided by the number of prescribed doses, was 91.7% in the GM-SR group and 88.6% in the GM-IR group (P < 0.001). The percentage of treatment days with the correct number of doses taken was 85.3% in the GM-SR group and 75.1% in the GM-IR group (P < 0.001). The percentage of missed doses was 11.7% in the GM-SR group and 15.3% in the GM-IR group (P < 0.001). The percentage of doses taken in the correct time window and therapeutic coverage were higher in the GM-SR group (P < 0.001). There was no significant difference in glycosylated hemoglobin changes or number of adverse events between the 2 groups. A total of 168 patients randomized to receive GM-SR once daily (86 patients) or GM-IR twice daily (82 patients). Mean Age were 57.8 +/- 9.6 years old. Male : female ratio was 47.6 : 52.4 %. Body mass index were 66.3 +/- 12.0 kg/m2, Diabetes duration were 10.5 +/- 6.6 years. (C) 2018 Elsevier HS Journals, Inc. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/976)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.